Day: March 30, 2022

ESEARCH TRIANGLE PARK, NC, March 30, 2022 (GLOBE NEWSWIRE) — Data443 Risk Mitigation, Inc. (“Data443” or the “Company”) (OTCPK: ATDSD, OTCPK: ATDS), the leading data security and privacy software company for ALL THINGS DATA SECURITY™, today announced that it will release financial results for the fiscal year ended December 31, 2021 after the market closes on Thursday, March 31st. Data443 will host a webcast on Monday, April 4th at 4:30pm. Eastern Time to discuss the company’s financial results and provide an update on its pursuit of an up-list to a national exchange. Interested parties can access the webcast by registering at www.data443.com or by clicking: https://data443.zoom.us/webinar/register/WN_n66YIixsSlOzLKgJeuVDbg. The webcast will be led by Jason Remillard, Founder and CEO of Data443. Investors may submit written questions...

CALGARY, Alberta, March 30, 2022 (GLOBE NEWSWIRE) — Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is publishing the attached message from its President and CEO, Neal Coleman, for Pulse’s shareholders, stakeholders and prospective investors. This message is also available on SEDAR (www.sedar.com) and on Pulse’s website at www.pulseseismic.com. CORPORATE PROFILE Pulse is a market leader in the acquisition, marketing and licensing of 2D and 3D seismic data to the western Canadian energy sector. Pulse owns the largest licensable seismic data library in Canada, currently consisting of approximately 65,310 square kilometres of 3D seismic and 829,207 kilometres of 2D seismic. The library extensively covers the Western Canada Sedimentary Basin where most of Canada’s oil and natural gas exploration and development...

LOUISVILLE, Ky., March 30, 2022 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (“CDI” or the “Company”) (Nasdaq: CHDN) today announced that CDI Escrow Issuer, Inc. (the “Escrow Issuer”), a wholly owned subsidiary of CDI, successfully priced an upsized offering of $1,200 million in aggregate principal amount of its 5.750% senior notes due 2030 (the “Notes”). The offering of the Notes is expected to close on April 13, 2022, subject to customary closing conditions. The offering of the Notes is part of the financing for the proposed acquisition by CDI of substantially all of the assets of Peninsula Pacific Entertainment LLC (“P2E”), a Delaware limited liability company (the “Acquisition”). The proceeds of the proposed offering will be placed in escrow pending satisfaction of certain conditions, including, without limitation, the consummation...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 30, 2022 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.WT, SUGR.WS, SUGR.WR, SUGR.DB) (OTCQB: SBUDF) (“Sugarbud” or the “Company“) announces that it has agreed to amend the terms of its previously announced marketed public offering (the “Offering”) of convertible debenture units (each a “Debenture Unit“) to: (i) lower the conversion price at which the convertible debentures of the Company (each a “Convertible Debenture”) are convertible into common shares of the Company (“Common Shares”) from $1.39 to $1.29 per Common Share, representing the closing market price of the Common Shares on March 30, 2022; (ii) lower the exercise price at which the Common Share purchase...

Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission. The Company was not enrolling any new patients in the trials placed on hold in the United States....